Back to search results

Pulsed Electromagnetic Field Therapy for Coronary Artery Disease

This study is investigating a device called Bioboosti, which uses Pulsed Electromagnetic Field (PEMF) therapy, to see if it can improve blood flow to the heart in people with coronary artery disease (CAD). PEMF therapy is a non-invasive technique that uses low-energy electromagnetic fields. You might be able to join if you are at least 18 years old, have known cardiac ischemia (reduced blood flow to the heart muscle) that cannot be treated with other procedures, and have evidence of ischemia from recent tests. Your heart's pumping ability (Left Ventricular Ejection Fraction) must also be above 40%. The researchers will measure changes in your heart's blood flow after 6 months of treatment to see if the therapy is successful. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 120 participants. It compares active Pulsed Electromagnetic Field (PEMF) therapy with an inactive PEMF device.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your myocardial blood flow will be measured after 6 months of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05111288

Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia

Recruiting
NAAges 18+Interventional
Mayo Clinic
~120 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:Pulsed electromagnetic field therapy (PEMF)Inactive Pulsed electromagnetic field therapy (PEMF)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Myocardial blood flow during chemical stress
Measured over change from baseline to post 6 months treatment

Conditions

Coronary Artery Disease
Myocardial Infarction

Explore related trials

Coronary Artery DiseaseExercise induced ischemiaMyocardial Infarction

Where it's being run

2 sites across 2 states
Arizona1
Minnesota1

Study leadership

  • Courtney Wheatley-Guy, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
  • Bruce Johnson, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Jordan Parks
[email protected]
480-301-6616
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years old.
Known cardiac ischemia, who are non revascularizable, or have not and will not be undergo coronary intervention for the duration of their participation in the study.
Evidence of ischemia from previous clinical tests (echo, nuclear, standard ECG from past 6 months).
Left Ventricular Ejection fraction \> 40% by echo (evaluated last 3 months).
Able to complete a cardiopulmonary exercise test without significant non cardiac limitations, primarily orthopedic.
On guideline directed optimal therapy for stable ischemia.

Exclusion

Anemia (\< 7 mg/dl).
Low potassium (\< 3 mmol/L).
Creatinine (\> 5.0 mg/dl or \< 0.6 mg/dl).
Unable to exercise due primarily to orthopedic limitation.
Severe lung disease.
Morbid obesity (BMI \> 42).
Pregnant.
Breast feeding.
Significant arrhythmia (ventricular tachycardia, ventricular fibrillation, frequent premature ventricular contractions (PVCs), persistent atrial fibrillation, or 2nd or 3rd degree atrioventricular (AV) block).
Seizures.
Unstable angina.
Coronary spasm.
Recent myocardial infarction (\< 90 days).
Recent percutaneous coronary intervention (\<90 days).

What this trial measures

  • Myocardial blood flow during chemical stresschange from baseline to post 6 months treatment

    assessment of myocardial blood flow using 13N-ammonia myocardial perfusion positron emission tomography (PET) to quantify blood flow during chemical induced stress